Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis
- PMID: 26765646
- DOI: 10.1016/S2352-3026(15)00228-8
Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis
Abstract
Background: Venous thromboembolism is a major global health problem that is often secondary to other clinical situations. Many studies have investigated the association between venous thromboembolism and heart failure, but have yielded inconsistent findings. We aimed to quantify the absolute and relative risks (RR) for venous thromboembolism in patients with heart failure after hospital admission. We also assessed rates of venous thromboembolism in patients in different settings.
Methods: In this systematic review and meta-analysis, we searched for studies investigating the risk of venous thromboembolism in patients in hospital with heart failure. We searched for studies published between Jan 1, 1955, and March 31, 2015, in PubMed, Embase, Evidence-Based Medicine Reviews, Allied and Complementary Medicine Database, Ovid HealthSTAR, Global Health, Ovid Nursing Database, Web of Science, CINAHL Plus, ProQuest Central, Conference Papers Index, BIOSIS Previews, and ClinicalTrials.gov. All cohort studies and subgroup analyses of randomised controlled trials (RCTs) were eligible for inclusion if they reported venous thromboembolism rates (number of events per follow-up period) or RR estimates. We extracted data from published reports and contacted the corresponding authors of records with insufficient quantitative data. RRs and 95% CIs were pooled using a random-effects model. This study is registered with PROSPERO, number CRD42014015504.
Findings: Of 8673 records identified, we included 71 studies with data from 88 cohorts in our analysis, with 59 cohorts included in the assessment of venous thromboembolism rates and 46 cohorts included in the meta-analysis of heart failure and risk of venous thromboembolism. Venous thromboembolism rates varied widely in patients in hospital with heart failure from different settings. The overall median symptomatic venous thromboembolism rate was 2·48% (IQR 0·84-5·61); rates was were 3·73% (1·05-7·31) for patients who did not receive thromboprophylaxis and 1·47% (0·64-3·54) for those who did. Overall, patients with heart failure in hospital had an RR of 1·51 (1·36-1·68) for venous thromboembolism. The overall I(2) statistic was 96·1% and there was no evidence of publication bias (Egger's test, p=0·46).
Interpretation: Heart failure is a common independent risk factor for venous thromboembolism. Thromoboprophylaxis should be considered in clinical practice for high-risk patients.
Funding: National Natural Science Foundation.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Comment in
-
Venous thromboembolism: Thromboprophylaxis for patients with HF.Nat Rev Cardiol. 2016 Feb;13(2):62-3. doi: 10.1038/nrcardio.2015.198. Epub 2015 Dec 24. Nat Rev Cardiol. 2016. PMID: 26701215 No abstract available.
-
Risk of venous thromboembolism in patients with heart failure.Lancet Haematol. 2016 Jan;3(1):e6-7. doi: 10.1016/S2352-3026(15)00249-5. Epub 2015 Dec 4. Lancet Haematol. 2016. PMID: 26765649 No abstract available.
Similar articles
-
Mortality risk associated with venous thromboembolism: a systematic review and Bayesian meta-analysis.Lancet Haematol. 2020 Aug;7(8):e583-e593. doi: 10.1016/S2352-3026(20)30211-8. Lancet Haematol. 2020. PMID: 32735837
-
Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis.Lancet Haematol. 2017 Feb;4(2):e83-e93. doi: 10.1016/S2352-3026(16)30184-3. Epub 2017 Jan 13. Lancet Haematol. 2017. PMID: 28089655 Review.
-
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.JAMA. 2008 Nov 19;300(19):2277-85. doi: 10.1001/jama.2008.656. JAMA. 2008. PMID: 19017914 Review.
-
Thromboprophylaxis for trauma patients.Cochrane Database Syst Rev. 2013 Mar 28;(3):CD008303. doi: 10.1002/14651858.CD008303.pub2. Cochrane Database Syst Rev. 2013. PMID: 23543562 Review.
-
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure.Cochrane Database Syst Rev. 2014 Apr 29;(4):CD007888. doi: 10.1002/14651858.CD007888.pub2. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2016 Dec 24;12:CD007888. doi: 10.1002/14651858.CD007888.pub3. PMID: 24777540 Updated. Review.
Cited by
-
Multimorbidity disease clusters are associated with venous thromboembolism: an extended cross-sectional national study.J Thromb Thrombolysis. 2024 Aug;57(6):898-906. doi: 10.1007/s11239-024-02987-y. Epub 2024 Apr 27. J Thromb Thrombolysis. 2024. PMID: 38678153 Free PMC article.
-
Prognostic Significance of Heart Failure in Acute Pulmonary Embolism: A Comprehensive Assessment of 30-Day Outcomes.J Clin Med. 2024 Feb 24;13(5):1284. doi: 10.3390/jcm13051284. J Clin Med. 2024. PMID: 38592126 Free PMC article.
-
Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure.J Health Econ Outcomes Res. 2024 Feb 20;11(1):44-56. doi: 10.36469/001c.92408. eCollection 2024. J Health Econ Outcomes Res. 2024. PMID: 38390025 Free PMC article.
-
Risk factors for venous thromboembolism in patients with pneumonia in the pre-COVID-19 era: a meta-analysis and systematic review.J Thorac Dis. 2023 Dec 30;15(12):6697-6707. doi: 10.21037/jtd-23-926. Epub 2023 Dec 26. J Thorac Dis. 2023. PMID: 38249878 Free PMC article.
-
The Optimal Management of Patients with Atrial Fibrillation and Acute Heart Failure in the Emergency Department.Medicina (Kaunas). 2023 Dec 2;59(12):2113. doi: 10.3390/medicina59122113. Medicina (Kaunas). 2023. PMID: 38138216 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
